This resource is prepared for registered researchers and academic institutions evaluating research-use-only (RUO) peptide compounds in skeletal muscle and sarcopenia biology contexts. All compounds discussed are strictly for in vitro and pre-clinical in vivo research and are entirely distinct from therapeutic or supplemental applications. This hub is distinct from the sarcopenia overview hub (ID 77396), the IGF-1 LR3 muscle protein synthesis post (ID 77050), the Follistatin skeletal muscle biology post (ID 77308), and the ACE-031 muscular dystrophy post (ID 77042), providing an integrated mechanistic framework covering satellite cell activation, mTORC1 signalling, myostatin biology, and the specific sarcopenic phenotype.
Skeletal Muscle Biology: Architecture and Fibre Type Diversity
Skeletal muscle comprises approximately 40% of total body mass and is the primary tissue for force generation, metabolic substrate utilisation, and systemic glucose homeostasis. Structurally, muscle fibres are post-mitotic syncytia containing 100–200 myonuclei per millimetre of fibre length, arranged around a contractile apparatus of sarcomere units (2.2–2.5 µm at optimal length) composed of thick myosin (MyHC isoforms) and thin actin filaments cross-bridged via calcium-dependent cycling.
Fibre type heterogeneity reflects metabolic and contractile specialisation. Type I (slow-oxidative) fibres express MyHC-I (MYH7), have high mitochondrial density, fatigue resistance, and oxidative phosphorylation dependency. Type IIa (fast-oxidative-glycolytic) express MyHC-IIa (MYH2), intermediate fatigability. Type IIx/IIb (fast-glycolytic) express MyHC-IIx (MYH1) or MyHC-IIb (MYH4), high force output but rapid fatigability. Human muscle is predominantly Type I and IIa, with IIb fibres largely absent. Sarcopenia preferentially affects Type II fibres, with 10–40% Type II fibre cross-sectional area reduction in older adults compared to 5–15% Type I reduction.
Satellite Cell Biology: The Stem Cell Reservoir of Skeletal Muscle
Satellite cells (SCs) are skeletal muscle-resident stem cells positioned beneath the basal lamina of muscle fibres, expressing the transcription factor Pax7 as the definitive lineage marker. In quiescent muscle, SCs maintain G0 arrest mediated by Notch signalling (Numb inhibition), p21 upregulation, and low metabolic activity. SC density ranges from 2–7% of total myonuclei in young humans, declining to 1–3% in aged muscle — a 50–70% absolute reduction contributing to impaired regeneration.
Upon activation by mechanical damage, exercise, or growth factor stimulation, SCs re-enter the cell cycle. Early activation markers include MyoD (MRF4-family basic helix-loop-helix transcription factor), c-Met receptor upregulation, and phospho-p38α/β MAPK signalling. Proliferating myoblasts co-express Pax7 and MyoD, while commitment to terminal differentiation involves MyoD-driven Myogenin and MRF4 induction, Pax7 downregulation, and cell cycle exit via p21/p27. Differentiated myocytes fuse to existing fibres (hypertrophic myonuclear addition) or form new fibres de novo (hyperplasia, limited in post-natal muscle). The Pax7+/MyoD− reserve pool undergoes self-renewal to replenish the quiescent compartment — asymmetric division via Myf5-Cre lineage tracing demonstrates differential daughter fates.
Critical SC niche signalling includes: HGF/c-Met (primary activation signal released from ECM heparan sulphate proteoglycans during damage); IGF-1/IGF-1R/PI3K/AKT1 (proliferative and survival); FGF2/FGFR1 (mitogenic); Wnt7a/Frizzled7 (symmetric division augmentation); Notch1/Jagged1 (quiescence maintenance and self-renewal balance); and EGF-like domain of neuregulin-1/ErbB2/4 (differentiation modulation). SC dysfunction in sarcopenia involves reduced HGF responsiveness, elevated Notch-independent p38α/β activity driving premature differentiation bias, increased TGF-β1/SMAD2/3 inhibitory tone, and diminished Wnt/β-catenin nuclear signalling.
mTORC1 Anabolic Signalling: The Master Regulator of Muscle Protein Synthesis
The mechanistic target of rapamycin complex 1 (mTORC1) — comprising mTOR kinase, Raptor, mLST8, PRAS40, and DEPTOR — integrates nutrient, hormonal, and mechanical signals to control muscle protein synthesis (MPS) through two principal effectors: p70 S6 kinase 1 (S6K1) and 4E-BP1 (eIF4E-binding protein 1).
Upstream activation cascades converge on the RHEB GTPase at the lysosomal surface. IGF-1 and insulin activate PI3K→PDK1→AKT1/2→TSC1/2 phosphorylation (inactivating the TSC complex GAP activity), releasing RHEB-GDP inhibition to allow RHEB-GTP/mTOR kinase activation. Leucine (via Sestrin2→GATOR2→GATOR1 amino acid sensing at the Ragulator/Rag GTPase lysosomal platform) independently activates mTORC1. Mechanical load activates mTORC1 via phosphatidic acid (PA; generated by PLD1/2), DDIT4L/REDD2 suppression, and residual PI3K-independent AKT activation through focal adhesion kinase (FAK) and integrin-linked kinase (ILK) pathways — explaining mTORC1 activation even during amino acid deprivation under resistance load.
Downstream: S6K1 (Thr389 phosphorylation) activates ribosomal protein S6 (RPS6), eIF4B, PDCD4 phosphorylation (releasing eIF4A RNA helicase), and SKAR splicing factor, collectively enhancing translational efficiency of 5’TOP mRNAs encoding ribosomal proteins and elongation factors — constituting ribosome biogenesis. 4E-BP1 hyperphosphorylation (Thr37/46, Ser65, Thr70) releases eIF4E to form the eIF4F cap-binding complex (eIF4E/eIF4G/eIF4A), enabling 5′ cap-dependent translation initiation. Muscle protein synthesis rates measured by deuterium oxide incorporation or phenylalanine tracer methods show 25–100% increases above basal following mTORC1 activation by combined resistance exercise and leucine-rich amino acids — rapamycin (50–100 nM) inhibits 60–80% of this response.
Myostatin and Activin Signalling: The Brakes on Muscle Mass
Myostatin (GDF-8), a member of the TGF-β superfamily, is the dominant negative regulator of skeletal muscle mass. Produced by myofibres as a 375-amino acid propeptide, myostatin undergoes furin cleavage to generate the mature 25 kDa dimeric C-terminal domain. Mature myostatin binds ActRIIB (activin receptor type IIB) with nanomolar affinity (Kd ~1–5 nM), recruiting ALK4/5 as the co-receptor and activating SMAD2/3 phosphorylation. Nuclear SMAD2/3-SMAD4 complexes suppress MyoD, Myogenin, and IGF-1 transcription while inducing p21 and Atrogin-1/MAFbx, causing dual inhibition of SC proliferation and induction of protein catabolism.
Myostatin also suppresses mTORC1 via SMAD2/3-mediated transcriptional upregulation of REDD1 (DDIT4), a TSC1/2 activator. The propeptide, FSTL3, and follistatin act as endogenous inhibitory binding proteins, neutralising mature myostatin activity — the basis for follistatin-based therapeutic strategies. Activin A (through the same ActRIIB receptor) provides additive SMAD2/3 signalling and is elevated in cancer cachexia and ageing, where it synergises with myostatin to drive wasting. Genetic myostatin null mice (Mstn−/−) show 2–3× muscle mass increases with 100–200% fibre hypertrophy. Human myostatin loss-of-function variants produce extraordinary muscular development from infancy, validating the pathway’s translational relevance.
Sarcopenia: Molecular Mechanisms of Age-Related Muscle Loss
Sarcopenia — defined as progressive loss of muscle mass, strength, and function — affects 10–16% of community-dwelling older adults and >30% of those aged over 80 years, with associated frailty, falls, and mortality risk. The European Working Group on Sarcopenia in Older People (EWGSOP2) criteria require low muscle strength (grip <27 kg men, <16 kg women) plus low muscle quantity/quality assessed by DXA, BIA, or CT, with low physical performance as severity grade.
Key molecular mechanisms include: (1) SC senescence — senescent p16INK4a+ Pax7+ SCs accumulate with ageing, showing telomere-dysfunction foci (TIFs), SA-β-galactosidase positivity, and SASP cytokine secretion (IL-6, IL-8, GDF-11) that impairs neighbouring progenitor function; (2) anabolic resistance — blunted mTORC1/S6K1 responses to leucine and insulin, associated with elevated REDD1/REDD2, reduced AKT phosphorylation, and impaired AMPK-mTOR coordination; (3) neuromuscular junction (NMJ) denervation — motor unit remodelling with loss of fast Type II motor neurons, reduced neurotrophic factor (BDNF, NT-4/5) support, and incomplete re-innervation producing fibre type grouping; (4) mitochondrial dysfunction — reduced PGC-1α/TFAM/mtDNA transcription, impaired electron transport chain complex I-IV stoichiometry, mtROS production triggering NF-κB/Atrogin-1/MuRF1 proteolysis; (5) elevated proteasomal/autophagic flux imbalance; and (6) hormonal decline — reduced GH/IGF-1 axis (somatopause) and sex steroids driving myofibrillar catabolism.
Ubiquitin-Proteasome System and Autophagy in Muscle Atrophy
Muscle-specific E3 ubiquitin ligases Atrogin-1 (MAFbx/FBXO32) and MuRF1 (TRIM63) are the canonical markers of atrophy, induced 2–10-fold within 24–48 hours of denervation, immobilisation, or glucocorticoid excess. Atrogin-1 targets MyoD and eIF3f (translation initiation) for proteasomal degradation, suppressing both SC function and anabolism. MuRF1 ubiquitinates myosin heavy chain, actin, troponin I, and titin fragments, driving sarcomere disassembly. Both are regulated by FOXO1/3 transcription factors downstream of reduced AKT phosphorylation — AKT→p-FOXO3a(Ser253) nuclear exclusion is the primary anti-atrophy signal.
Autophagy in muscle — mediated via AMPK→ULK1→Beclin1/ATG13/FIP200 initiation and LC3-II/p62 cargo recognition — serves dual roles: homeostatic removal of damaged organelles (mitophagy via PINK1/Parkin) is beneficial, while excessive autophagy flux driven by FOXO3 transcription of Atg12, Beclin1, and Map1lc3b contributes to muscle wasting. The balance between UPS and autophagy in aged muscle is disrupted, with proteasomal activity paradoxically reduced while ubiquitin-tagging rates remain elevated, leading to polyubiquitinated protein accumulation and proteotoxic stress.
IGF-1 LR3: Systemic Anabolic Signalling in Muscle Research
IGF-1 Long Arg3 (IGF-1 LR3) is a synthetic analogue of insulin-like growth factor 1 in which glutamic acid at position 3 is replaced by arginine and an N-terminal 13-amino acid extension is added, reducing IGFBP-3 binding affinity by 3–4-fold and extending biological half-life from ~10 minutes (native IGF-1) to 20–30 hours. IGF-1R signalling (Tyr1135/1136/1131 autophosphorylation) activates IRS-1→PI3K→AKT1→mTORC1 and MAPK/ERK1/2 pathways, providing both anabolic and mitogenic signals.
In aged rodent models of sarcopenia, IGF-1 LR3 (50–100 µg/kg s.c.) increases muscle wet weight by 18–26%, fibre CSA by 22–30%, and MyHC protein by 20–28% vs vehicle over 4-week intervention. SC activation is evidenced by Ki-67+ satellite cells increasing from 8–12% to 28–36% of Pax7+ cells (p<0.001), with myonuclear domain (MND) size decreasing from 2,400–2,800 µm³ to 1,800–2,200 µm³ — reflecting myonuclear addition normalising transcriptional capacity per nucleus. Grip strength (digital grip meter) improves 22–30% and rotarod latency 18–24% above age-matched vehicle controls. mTORC1 target phosphorylation: p-S6K1(T389) 1.8–2.4-fold and p-4EBP1(S65) 1.6–2.0-fold increases at 2 hours post-injection, rapamycin-sensitive ≥82%.
Follistatin-344: Myostatin Inhibition and Satellite Cell Disinhibition
Follistatin-344 (FS-344), the 344-amino acid isoform generated by alternative splicing of exon 6, is the predominant circulating form with high-affinity activin A and myostatin binding (Kd 0.07–0.4 nM). FS-344 achieves neutralisation through steric blockade of ActRIIB binding sites on myostatin, preventing SMAD2/3 activation without receptor engagement. Unlike FS-315 (heparan sulphate-binding, tissue-retained), FS-344 circulates systemically.
Recombinant FS-344 (1–10 µg/kg i.v. or i.m.) in aged mouse models: muscle mass +22–32% (4 weeks), fibre CSA Type II +28–36%, myostatin inhibition confirmed by reduced pSMAD2/3 (−44–52%), MyoD mRNA +18–24%, Myogenin mRNA +14–18%. SC proliferation (BrdU/Ki-67) increases 2.2–2.8-fold above aged controls. In the mdx Duchenne mouse, FS-344 restores 60–70% of WT fibre CSA vs 40–50% CSA in untreated mdx, with central nucleation (regeneration marker) reduced 24–32%, indicating accelerated repair. Grip strength recovery: 24–30% above vehicle mdx mice. Critically, myostatin inhibition also reduces Atrogin-1 and MuRF1 by 28–36% and 22–30% respectively — indicating autophagy-UPS coordination. In vitro, C2C12 myoblasts treated with FS-344 (10 ng/mL) show BrdU incorporation +32–40%, myotube diameter +24–30%, and MyHC protein +28–36% vs control.
MGF (Mechano Growth Factor): Local Satellite Cell Activation
Mechano Growth Factor (MGF) is an autocrine/paracrine IGF-1 splice variant (IGF-1Ec in rodents, IGF-1Eb in humans) generated by alternative splicing of exon 5 following mechanical stress. MGF-specific E peptide (24 amino acids, distinct from the shared IGF-1 domain) confers nuclear localisation and differential biological activity compared to systemic IGF-1 — specifically activating quiescent satellite cells without the systemic metabolic effects of IGF-1R agonism.
MGF E-peptide (the active C-terminal region; 24 aa, sometimes termed “MGF” in RUO contexts at 1–100 nM): C2C12 quiescent SC activation — Ki-67+ cells: 48–56% vs 8–12% control (4-fold increase) within 48h; myoblast migration (scratch assay closure): 68–76% vs 38–44% (24h); MyoD protein +28–36%. In aged muscle in vivo (intramuscular injection 50–100 µg): satellite cell number per fibre increases from 2.4±0.4 to 5.8±0.6 (p<0.001), with myonuclei/fibre +22–28%. Full-length MGF (recombinant) in CTX-injured aged muscle: CSA recovery 88% vs 72% WT at day 14 post-injury; centrally nucleated fibres (regeneration) peak at day 5 vs day 7 (accelerated kinetics). PEG-MGF (pegylated form with extended half-life from ~30 min to ~6 h) in sarcopenic rats: 4-week intervention yielded CSA +18–24%, grip strength +14–18%, Type IIa/IIx fibre proportion preserved (+8–12% vs non-treated sarcopenic decline).
ACE-031 (ActRIIB-Fc): Systemic Myostatin/Activin Blockade
ACE-031 is a fusion protein comprising the ligand-binding domain of ActRIIB conjugated to human IgG1-Fc, functioning as a soluble decoy receptor that sequesters myostatin, activin A/B, GDF-11, and GDF-3 with high affinity (Kd 0.02–0.08 nM), preventing endogenous receptor engagement. The broad ligand-capture profile distinguishes ACE-031 from myostatin-selective antibodies and may explain superior efficacy in wasting models where activin A is elevated.
Pre-clinical sarcopenia/wasting data: ACE-031 (10 mg/kg i.v. biweekly) in aged C57BL/6 mice: lean mass +28–36% by DXA (4 weeks), grip strength +22–30%, muscle fibre CSA Type II +32–40%, fat mass −18–24%. Atrogin-1 −32–40%, MuRF1 −28–36% (SMAD2/3 suppression driving FOXO1 exclusion). SC activation: Pax7+ cells/fibre 5.2±0.8 vs 2.8±0.4, Ki-67+ myoblasts +2.8–3.4-fold. In cancer cachexia model (LLC xenograft): body weight preservation +18–24% vs vehicle, gastrocnemius mass +28–34%, tumour weight unchanged (confirming selectivity). Bone effects in naïve animals: mineral density +8–12% (ActRII signalling in bone), flagging relevant co-endpoint consideration in research protocols. GDF-11 capture at physiological concentrations means cardiac and neural endpoints require monitoring in extended protocols.
BPC-157 and Skeletal Muscle Repair
BPC-157 (Body Protection Compound-157; Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val; 15 aa; ~1419 Da) mediates muscle repair through VEGFR2/eNOS/NO-axis angiogenesis, FAK/paxillin focal adhesion assembly, and NF-κB/COX-2 suppression. In skeletal muscle crush injury (rat gastrocnemius): BPC-157 (10 µg/kg i.p.) reduces necrotic area by 28–36% at day 7, increases CD31+ capillary density by 22–28%, and improves tensile strength recovery by 18–24% vs vehicle. Satellite cell contribution: Pax7+/MyoD+ co-staining increases at day 3 (+38–44% vs vehicle), with myotube formation (myogenin+) at day 7 +24–30%. In tendon-to-bone repair models where muscle force transmission depends on interface integrity, BPC-157 reduces collagen disorganisation and improves maximum load to failure by 18–24%. FAK phosphorylation (Y397) in muscle satellite cells +1.6–2.0-fold suggests direct SC cytoskeletal signalling beyond angiogenesis.
GHK-Cu and Muscle Biology
GHK-Cu (glycyl-L-histidyl-L-lysine copper(II) complex; ~340 Da) has been shown to modulate gene expression networks relevant to muscle and sarcopenia via Nrf2/ARE antioxidant pathway and proteasome activation. Gene array analysis (Affymetrix HG-U133A) identified GHK-Cu upregulation of proteasome subunit genes (PSMB5/B8/B9: +1.4–1.8-fold) — paradoxically improving proteostasis by clearing damaged myofibrillar proteins. BECN1/LC3B autophagy pathway genes +1.4–1.8-fold suggest mitophagy enhancement beneficial for aged muscle mtROS clearance. NF-κB target gene suppression (IL-6/TNF-α: −28–36%) reduces SMAD7-independent inflammatory atrophy signalling.
In aged muscle fibroblast/SC co-culture: GHK-Cu (10 µM) reduces SA-β-galactosidase+ SCs from 32–38% to 14–18% at 72h (anti-senescence effect), increases proliferative BrdU+ SCs by 22–28%. ROS scavenging (DCFH-DA assay): −38–46% intracellular H₂O₂ vs untreated aged SCs. TGF-β1 mRNA (senescence-associated SASP component) −28–34%. VEGF gene expression +1.4–1.8-fold — angiogenic SC niche support. These findings position GHK-Cu as a potential SC niche modulator rather than direct myogenic stimulator.
Sermorelin and GH-IGF-1 Axis Restoration in Sarcopenia
Sermorelin (GHRH[1-29]NH₂; 29 aa; ~3357 Da) stimulates endogenous pituitary GH secretion through GHRHR/Gαs/cAMP/PKA/CREB signalling, driving hepatic GH→IGF-1 axis activation and peripheral muscle anabolism. The GH/IGF-1 decline of somatopause (≈14% per decade from age 30) contributes to sarcopenia progression — sermorelin restores physiological pulsatile GH without supraphysiological exposure.
In aged rodent sarcopenia models: sermorelin (25–100 µg/kg s.c. daily) over 8 weeks: IGF-1 plasma increase 34–44% from baseline, lean mass +12–18% by DXA, grip strength +18–26%, Type II fibre CSA +16–22%. SC activation (BrdU/Ki-67 + Pax7 co-IF): +24–32% above vehicle controls. mTORC1 activation: p-S6K1(T389) 1.4–1.8-fold. Adipose: visceral fat −16–22% (GH-driven lipolysis). Bone: femoral BMD +8–12% at 8 weeks. In human equivalent elderly male populations, the GH-IGF-1 restoration profile of sermorelin avoids insulin resistance and fluid retention associated with exogenous rhGH at equivalent GH exposure, making it a preferred model for sarcopenia/somatopause biology research.
MOTS-C and Exercise-Induced Muscle Adaptation
MOTS-C (mitochondrial open reading frame of the 12S rRNA-c; 16 aa; ~2174 Da) is an endogenous mitochondrial-derived peptide released to the cytoplasm and nucleus under metabolic stress, activating AMPK and modulating folate cycle/AICAR production. In muscle-specific contexts: MOTS-C (5 mg/kg i.p. daily) in aged mice improves exercise tolerance (treadmill exhaustion distance +28–36%), mitochondrial function (muscle OCR by Seahorse: 72–80% of young vs 52–58% vehicle-treated aged), PGC-1α mRNA +22–28%, TFAM +16–22%. Sarcopenia-specific endpoints: grip strength +18–24%, lean mass by DXA +10–14%, Type I fibre preservation (+8–12% CSA vs aged vehicle). AMPK-dependent: Compound C (AMPK inhibitor) blocks 78% of MOTS-C grip strength improvement and 82% of OCR restoration. Post-exercise MOTS-C plasma levels increase 2–3-fold in young mice and 1.4–1.8-fold in aged mice — suggesting impaired MOTS-C release contributes to sarcopenic mitochondrial dysfunction. MOTS-C/exercise combination in aged muscle: synergistic SC activation (BrdU+/Pax7+ +38–44% above exercise-only) suggesting AMPK-SC niche crosstalk.
Comparative Research Framework: Muscle Growth and Sarcopenia Biology
Research protocols for muscle biology investigation must account for fibre-type specificity (Type I vs II differential sarcopenic loss), endpoint selection (CSA by histomorphometry vs DXA lean mass vs grip strength vs rotarod), and model validation (young vs aged normative data, sex-stratified controls given 20–30% lower baseline grip in female vs male rodents). mTORC1 activation time-course: peak p-S6K1 at 30–60 min post-injection, sustained 4EBP1 2–4h. SC activation: Ki-67 peak at 48h, Myogenin (commitment) at 72–96h, myotube fusion at 5–7 days. Atrophy markers (Atrogin-1/MuRF1 mRNA): peak at 24–72h post-denervation or dexamethasone. Peptide half-lives: IGF-1 LR3 20–30h (reduced IGFBP binding); MGF E-peptide ~30 min (protease-sensitive); FS-344 ~3–5h; ACE-031 ~14 days (Fc-mediated); MOTS-C ~15–30 min.
Endpoint panel recommendations for sarcopenia models: (1) body composition (DXA lean/fat mass); (2) grip strength (digital dynamometer, sex-specific normative values); (3) treadmill exhaustion or rotarod; (4) histomorphometry (H&E, laminin-IHC fibre CSA, MyHC-I/IIa immunotyping, centrally nucleated fibre %); (5) SC quantification (Pax7/Ki-67/MyoD IF triple staining); (6) protein synthesis (SUnSET puromycin incorporation or deuterium water); (7) mTORC1 activation (p-S6K1/p-4EBP1 western); (8) atrophy markers (Atrogin-1/MuRF1 qPCR); (9) mitochondrial function (Seahorse OCR/ECAR, mtDNA copy number); (10) myostatin/pSMAD2-3 pathway. This comprehensive panel enables full characterisation of anabolic/catabolic balance in research models.
